Ohashi Takuya, Yoshimasu Tatsuya, Oura Shoji, Kokawa Yozo, Kawago Mitsumasa, Hirai Yoshimitsu, Miyasaka Miwako, Aoishi Yuka, Kiyoi Megumi, Nishiguchi Haruka, Honda Mariko, Okamura Yoshitaka
Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University, Wakayama, Japan
Department of Thoracic and Cardiovascular Surgery, Wakayama Medical University, Wakayama, Japan.
Anticancer Res. 2015 May;35(5):2669-74.
In order to clarify whether class III beta-tubulin (TUBB3) is a predictive marker for paclitaxel (PTX) chemotherapy, chemosensitivity was examined using an in vitro drug sensitivity assay.
Twelve specimens from non-small cell lung cancer (NSCLC) patients were obtained for dose-response curve analysis and measurement of the half-maximal effective dose (ED50) of PTX using the histoculture drug response assay (HDRA). Forty-one specimens were evaluated using the HDRA and the inhibition ratio (IR) at a concentration of 25 μg/ml PTX (IR25) was measured. TUBB3 expression was evaluated by H-score in immunohistochemical staining.
The ED50 of PTX was 24.5 ± 8.06 μg/ml. The median H-score was significantly higher (p=0.0076) in the high effective dose (HE)-group (ED50 >25 μg/ml) than in the low effective (LE)-group (ED50 ≤ 25 μg/ml). The mean IR25 was 53.8 ± 26.6%. The median H-score for the high-inhibition ratio (HI)-group (IR25 >50%) was significantly higher (p=0.0337) than the low-inhibition ratio (LI)-group (IR25 ≤ 50%).
High TUBB3 expression in NSCLC appeared to correlate with lower PTX sensitivity.
为了阐明Ⅲ类β微管蛋白（TUBB3）是否为紫杉醇（PTX）化疗的预测标志物，采用体外药敏试验检测化疗敏感性。
获取12例非小细胞肺癌（NSCLC）患者的标本用于剂量反应曲线分析，并使用组织培养药物反应试验（HDRA）测量PTX的半数最大效应剂量（ED50）。使用HDRA对41例标本进行评估，并测量PTX浓度为25μg/ml时的抑制率（IR）（IR25）。通过免疫组织化学染色的H评分评估TUBB3表达。
PTX的ED50为24.5±8.06μg/ml。高效组（ED50>25μg/ml）的中位H评分显著高于低效组（ED50≤25μg/ml）（p=0.0076）。平均IR25为53.8±26.6%。高抑制率组（IR25>50%）的中位H评分显著高于低抑制率组（IR25≤50%）（p=0.0337）。
NSCLC中TUBB3高表达似乎与较低的PTX敏感性相关。
